RS58310495 Unknown gene
Upload your DNA to see your genotype for this variant.
GWAS Studies (14)
| Trait | Risk Allele | OR / Beta | P-value | Study |
|---|---|---|---|---|
| Plasma X-12456 levels in chronic kidney disease | T | OR: 0.4 | 2E-36 | PubMed |
| Eicosanodioate levels | T | OR: 0.16 | 2E-31 | PubMed |
| Metabolite levels (taurodeoxycholic acid 3-sulfate) | T | OR: 0.47 | 3E-29 | PubMed |
| 1-arachidonoyl-GPE (20:4n6) levels | T | OR: 0.23 | 4E-29 | PubMed |
| Urine cortisone 21-sulfate levels in chronic kidney disease | T | OR: 0.34 | 3E-23 | PubMed |
| Urinary metabolite levels in chronic kidney disease | T | OR: 0.59 | 1E-15 | PubMed |
| Eicosanedioate (C20-DC) levels | T | OR: 0.17 | 1E-15 | PubMed |
| Triglyceride percentage of total lipids in intermediate-density lipoprotein | T | β: 0.033 | 1E-14 | PubMed |
| Gout | T | OR: 0.95 | 4E-13 | PubMed |
| Response to statins (LDL cholesterol percent change)(baseline-unadjusted) | T | β: 0.069 | 7E-12 | PubMed |
| Hydroxy-cmpf (X-02269) levels | T | OR: 0.14 | 7E-12 | PubMed |
| Low density lipoprotein cholesterol levels (on statin treatment) | T | β: 0.016 | 2E-11 | PubMed |
| Response to statins (LDL cholesterol change) | T | β: 0.015 | 5E-11 | PubMed |
| Ceramide (d16:1/16:0) levels | T | OR: 0.17 | 2E-8 | PubMed |